AMENDMENT NO. 1 TO ACQUISITION AGREEMENTAcquisition Agreement • April 7th, 2016 • Avalanche Biotechnologies, Inc. • Biological products, (no disgnostic substances) • Delaware
This AMENDMENT NO. 1 TO ACQUISITION AGREEMENT (this “Amendment”), dated as of April 6, 2016, is entered into by and among Avalanche Biotechnologies, Inc., a Delaware corporation (“Parent”), Annapurna Therapeutics SAS, a French simplified joint stock company (the “Company”), and each of the persons listed as shareholders of the Company on the signature pages hereof (each, a “Contributor” and together, the “Contributors”). Parent, the Company and the Contributors shall collectively be referred to herein as the “Parties”. Capitalized terms used in this Amendment but not defined herein have the meanings ascribed to them in the Acquisition Agreement (as defined below).
